A Patient with Papillary Thyroid Carcinoma and Biochemical Incomplete Response with Gradually Increasing Tg Values and Negative Imaging Studies

  • Çiğdem Soydal
  • Elgin Özkan


A 61-year-old asymptomatic female patient having no risk factors for thyroid carcinoma underwent neck ultrasound. Following a diagnosis of papillary thyroid cancer (PTC) by fine needle aspiration biopsy, the patient underwent total thyroidectomy and right lateral neck lymph node dissection. Histopathological examination of the surgical specimen revealed two PTC foci in the right thyroidal lobe that were 4 cm and 0.1 cm in diameter. The patient received radioiodine ablation treatment (RAT) with 5550 MBq (150 mCi) iodine-131 (I-131) 3 months after the operation. Six months after RAT, diagnostic whole-body scintigraphy was performed with endogenous TSH stimulation with 185 MBq I-131. Serum TSH-stimulated Tg levels were 66.55 ng/mL, and I-131 scintigraphy revealed the absence of any pathological uptake. Neck ultrasound (US) and computed tomography (CT) of the thorax were normal. A 18F-FDG PET/BT was planned to search for possible recurrent disease, but it was determined normal. Serum thyroglobulin levels gradually increased to 89.79 ng/mL during the 8-year follow-up period. Several neck USGs, thorax CTs, and one additional 18F-FDG PET/CT were performed. Finally, cranial CT and Tc-99m MDP bone scintigraphy were performed. No residual or metastatic tissue detected so far.


Papillary thyroid carcinoma Increasing Tg values Incomplete biochemical response 


  1. 1.
    Matthews TJ, Chua E, Gargya A, Clark J, Gao K, Elliott M. Elevated serum thyroglobulin levels at the time of ablative radioactive iodine therapy indicate a worse prognosis in thyroid cancer: an Australian retrospective cohort study. J Laryngol Otol. 2016;130:50–3. Scholar
  2. 2.
    Park HJ, Jeong GC, Kwon SY, Min JJ, Bom HS, Park KS, et al. Stimulated serum thyroglobulin level at the time of first dose of radioactive iodine therapy is the most predictive factor for therapeutic failure in patients with papillary thyroid carcinoma. Nucl Med Mol Imaging. 2014;48:255–61. Scholar
  3. 3.
    Stevic I, Dembinski TC, Pathak KA, Leslie WD. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer. Clin Biochem. 2015;48:658–61. Scholar
  4. 4.
    Wiebel JL, Esfandiari NH, Papaleontiou M, Worden FP, Haymart MR. Evaluating positron emission tomography use in differentiated thyroid cancer. Thyroid. 2015;25:1026–32. Scholar
  5. 5.
    Hempel JM, Kloeckner R, Krick S, Pinto Dos Santos D, Schadmand-Fischer S, Boeßert P, et al. Impact of combined FDG-PET/CT and MRI on the detection of local recurrence and nodal metastases in thyroid cancer. Cancer Imaging. 2016;3:37. Scholar
  6. 6.
    Riola-Parada C, García-Cañamaque L, Pérez-Dueñas V, Garcerant-Tafur M, Carreras-Delgado JL. Simultaneous PET/MRI vs PET/CT in oncology. A systematic review. Rev Esp Med Nucl Imagen Mol. 2016;35:306–12. Scholar
  7. 7.
    Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, Takamura Y, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid. 2011;21:707–16. Scholar
  8. 8.
    Rössing RM, Jentzen W, Nagarajah J, Bockisch A, Görges R. Serum thyroglobulin doubling time in progressive thyroid cancer. Thyroid. 2016;26:1712–8. Scholar
  9. 9.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–159. Scholar
  10. 10.
    Leboulleux S, El Bez I, Borget I, Elleuch M, Déandreis D, Al Ghuzlan A, et al. Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels. Thyroid. 2012;22:832–8. Scholar
  11. 11.
    Vrachimis A, Stegger L, Wenning C, Noto B, Burg MC, Konnert JR, Allkemper T, et al. (68)Ga DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016;43:1765–72. Scholar
  12. 12.
    Elboğa U, Ozkaya M, Sayiner ZA, Çelen YZ. Lu-177 labelled peptide treatment for radioiodine refractory differentiated thyroid carcinoma. BMJ Case Rep. 2016.
  13. 13.
    Dercle L, Deandreis D, Terroir M, Leboulleux S, Lumbroso J, Schlumberger M. Evaluation of (124)I PET/CT and (124)I PET/MRI in the management of patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016;43:1006–10. Scholar
  14. 14.
    Santhanam P, Taieb D, Solnes L, Marashdeh W, Ladenson PW. Utility of I 124 PET/CT in identifying radioiodine avid lesions in differentiated thyroid cancer; a systematic review and meta-analysis. Clin Endocrinol. 2017;86(5):645–51. Scholar
  15. 15.
    Kuker R, Sztejnberg M, Gulec S. I-124 imaging and dosimetry. Mol Imaging Radionucl Ther. 2016;5:66–73. Scholar
  16. 16.
    Binse I, Poeppel TD, Ruhlmann M, Gomez B, Umutlu L, Bockisch A, et al. Imaging with (124)I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT? Eur J Nucl Med Mol Imaging. 2016;43:1011–7. Scholar
  17. 17.
    Vrachimis A, Burg MC, Wenning C, Allkemper T, Weckesser M, Schäfers M, et al. [(18)F]FDG PET/CT outperforms [(18)F]FDG PET/MRI in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016;43:212–20. Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Çiğdem Soydal
    • 1
  • Elgin Özkan
    • 2
  1. 1.Department of Nuclear MedicineAnkara University School of MedicineAnkaraTurkey
  2. 2.Department of Nuclear MedicineMedical Faculty of Ankara UniversityAnkaraTurkey

Personalised recommendations